Russell Investments Group Ltd. trimmed its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 5.3% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 256,265 shares of the medical instruments supplier’s stock after selling 14,234 shares during the quarter. Russell Investments Group Ltd.’s holdings in Becton, Dickinson and Company were worth $45,881,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the company. Moneco Advisors LLC increased its stake in Becton, Dickinson and Company by 2.6% during the 3rd quarter. Moneco Advisors LLC now owns 2,071 shares of the medical instruments supplier’s stock worth $371,000 after buying an additional 52 shares in the last quarter. Brown Lisle Cummings Inc. lifted its position in shares of Becton, Dickinson and Company by 9.2% in the second quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock valued at $97,000 after acquiring an additional 54 shares in the last quarter. Pension & Wealth Management Advisors Inc. lifted its position in shares of Becton, Dickinson and Company by 12.3% in the third quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier’s stock valued at $94,000 after acquiring an additional 56 shares in the last quarter. Brighton Jones LLC lifted its position in shares of Becton, Dickinson and Company by 0.7% in the third quarter. Brighton Jones LLC now owns 8,942 shares of the medical instruments supplier’s stock valued at $1,601,000 after acquiring an additional 58 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC boosted its stake in shares of Becton, Dickinson and Company by 3.7% in the second quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock worth $256,000 after acquiring an additional 60 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several analysts recently commented on the company. TD Cowen boosted their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada increased their price objective on Becton, Dickinson and Company from $190.00 to $225.00 and gave the company a “sector perform” rating in a research note on Friday, November 6th. UBS Group initiated coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price objective on the stock. Bank of America lifted their target price on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Monday, August 31st. Finally, JPMorgan Chase & Co. upped their target price on shares of Becton, Dickinson and Company from $170.00 to $202.00 and gave the stock a “neutral” rating in a report on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $197.47.
Insider Buying and Selling
In related news, CEO Thomas Polen, Jr. sold 2,993 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $210.00, for a total value of $628,530.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $23,134,230. This represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the transaction, the executive vice president owned 19,720 shares of the company’s stock, valued at $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 3,310 shares of company stock worth $688,650 over the last quarter. 0.40% of the stock is currently owned by insiders.
Becton, Dickinson and Company Price Performance
Becton, Dickinson and Company stock opened at $217.95 on Monday. The company has a current ratio of 0.87, a quick ratio of 0.54 and a debt-to-equity ratio of 0.54. The company has a 50-day moving average price of $190.90 and a 200 day moving average price of $170.56. Becton, Dickinson and Company has a 12-month low of $140.11 and a 12-month high of $219.78. The stock has a market cap of $60.05 billion, a P/E ratio of 52.64, a PEG ratio of 3.65 and a beta of 0.22.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.08. Becton, Dickinson and Company had a net margin of 5.66% and a return on equity of 14.90%. The company had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.11 billion. During the same period in the previous year, the business posted $3.96 EPS. Becton, Dickinson and Company’s revenue was up 5.4% on a year-over-year basis. Sell-side analysts anticipate that Becton, Dickinson and Company will post 13.21 earnings per share for the current year.
Becton, Dickinson and Company Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be given a dividend of $1.06 per share. This represents a $4.24 annualized dividend and a dividend yield of 1.9%. The ex-dividend date of this dividend is Thursday, December 10th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. Becton, Dickinson and Company’s dividend payout ratio is presently 101.45%.
Becton, Dickinson and Company announced that its Board of Directors has initiated a share repurchase program on Thursday, November 5th that allows the company to repurchase 10,000,000 shares. This buyback authorization allows the medical instruments supplier to purchase up to 3.6% of its stock through open market purchases. Share buyback programs are often a sign that the company’s management believes its shares are undervalued.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.
Featured Articles
- Five stocks we like better than Becton, Dickinson and Company
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
